BACKGROUND AND AIMS: Colorectal cancers exhibiting microsatellite instability (MSI) appear to have unique biological behavior. The influence of MSI on the prognosis of sporadic colorectal cancers is controversial and requires further investigation. The aim of this study was to analyze the association between MSI status and clinicopathological features and prognosis in sporadic colorectal cancer patients. PATIENTS AND METHODS: Of the 322 consecutive colorectal cancer patients operated upon at the Seoul National University Hospital between January and December 1998, we examined the clinicopathological features and prognosis of 248 patients with sporadic primary colorectal cancer. The MSI status of these 248 patients has been reported in a previous study. Of the 248 patients, 23 (9.3%) had MSI+ tumors. The patients' clinicopathological parameters were obtained from their medical records, and follow-up and survival data were obtained from medical records and phone calls. RESULTS: MSI+ sporadic colorectal cancers were found predominantly in the proximal colon ( p<0.001) and were associated with poor differentiation ( p=0.030), a lower preoperative serum carcinoembryonic antigen (CEA) level ( p=0.012), and less frequent systemic metastasis ( p=0.034) than MSI- tumors. Low tumor grade ( p=0.022), low tumor T-stage ( p=0.002), no lymph node metastasis ( p<0.001), no systemic metastasis ( p<0.001), adjuvant chemotherapy ( p<0.001) and MSI+ status ( p=0.038) were independent favorable prognostic factors for survival in sporadic colorectal cancer patients. CONCLUSION: MSI status was an independent favorable prognostic factor for survival in sporadic primary colorectal cancer patients.
BACKGROUND AND AIMS: Colorectal cancers exhibiting microsatellite instability (MSI) appear to have unique biological behavior. The influence of MSI on the prognosis of sporadic colorectal cancers is controversial and requires further investigation. The aim of this study was to analyze the association between MSI status and clinicopathological features and prognosis in sporadic colorectal cancerpatients. PATIENTS AND METHODS: Of the 322 consecutive colorectal cancerpatients operated upon at the Seoul National University Hospital between January and December 1998, we examined the clinicopathological features and prognosis of 248 patients with sporadic primary colorectal cancer. The MSI status of these 248 patients has been reported in a previous study. Of the 248 patients, 23 (9.3%) had MSI+ tumors. The patients' clinicopathological parameters were obtained from their medical records, and follow-up and survival data were obtained from medical records and phone calls. RESULTS: MSI+ sporadic colorectal cancers were found predominantly in the proximal colon ( p<0.001) and were associated with poor differentiation ( p=0.030), a lower preoperative serum carcinoembryonic antigen (CEA) level ( p=0.012), and less frequent systemic metastasis ( p=0.034) than MSI- tumors. Low tumor grade ( p=0.022), low tumor T-stage ( p=0.002), no lymph node metastasis ( p<0.001), no systemic metastasis ( p<0.001), adjuvant chemotherapy ( p<0.001) and MSI+ status ( p=0.038) were independent favorable prognostic factors for survival in sporadic colorectal cancerpatients. CONCLUSION: MSI status was an independent favorable prognostic factor for survival in sporadic primary colorectal cancerpatients.
Authors: K C Halling; A J French; S K McDonnell; L J Burgart; D J Schaid; B J Peterson; L Moon-Tasson; M R Mahoney; D J Sargent; M J O'Connell; T E Witzig; G H Farr; R M Goldberg; S N Thibodeau Journal: J Natl Cancer Inst Date: 1999-08-04 Impact factor: 13.506
Authors: M J Massa; P Iniesta; R González-Quevedo; C de Juan; T Caldés; A Sánchez-Pernaute; J Cerdán; A J Torres; J L Balibrea; M Benito Journal: Eur J Cancer Date: 1999-11 Impact factor: 9.162
Authors: V J Bubb; L J Curtis; C Cunningham; M G Dunlop; A D Carothers; R G Morris; S White; C C Bird; A H Wyllie Journal: Oncogene Date: 1996-06-20 Impact factor: 9.867
Authors: C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava Journal: Cancer Res Date: 1998-11-15 Impact factor: 12.701
Authors: H T Lynch; T C Smyrk; P Watson; S J Lanspa; J F Lynch; P M Lynch; R J Cavalieri; C R Boland Journal: Gastroenterology Date: 1993-05 Impact factor: 22.682
Authors: L A Aaltonen; P Peltomäki; F S Leach; P Sistonen; L Pylkkänen; J P Mecklin; H Järvinen; S M Powell; J Jen; S R Hamilton Journal: Science Date: 1993-05-07 Impact factor: 47.728
Authors: Cathy Wang; Marius van Rijnsoever; Fabienne Grieu; Sean Bydder; Hsny Elsaleh; David Joseph; Jennet Harvey; Barry Iacopetta Journal: Oncology Date: 2003 Impact factor: 2.935
Authors: P Peltomäki; R A Lothe; L A Aaltonen; L Pylkkänen; M Nyström-Lahti; R Seruca; L David; R Holm; D Ryberg; A Haugen Journal: Cancer Res Date: 1993-12-15 Impact factor: 12.701
Authors: Dominik Alexander; Nirag Jhala; Chakrapani Chatla; Jon Steinhauer; Ellen Funkhouser; Christopher S Coffey; William E Grizzle; Upender Manne Journal: Cancer Date: 2005-05-15 Impact factor: 6.860
Authors: Wilfredo E De Jesus-Monge; Carmen Gonzalez-Keelan; Ronghua Zhao; Stanley R Hamilton; Miguel Rodriguez-Bigas; Marcia Cruz-Correa Journal: Fam Cancer Date: 2010-06 Impact factor: 2.375